Deep Brain Stimulation in Treatment Resistant Schizophrenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2019-12-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims at assessing efficacy and safety of Deep Brain Stimulation (DBS) for treatment of patients with treatment resistant schizophrenia, by means of a random, controlled and crossed study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Deep Brain Stimulation Recovery in Treatment-Resistant Schizophrenia

NCT05337904

Treatment-resistant Schizophrenia Deep Brain Stimulation

ACTIVE_NOT_RECRUITING NA

DBS in Treatment Resistant Major Depression

NCT01268137

Resistant Major Depressive Disorder

UNKNOWN PHASE3

Exploration of the Deep Transcranial Magnetic Stimulation for Treatment Resistant Schizophrenia

NCT05167942

Treatment Resistant Schizophrenia Based on the DTMS

UNKNOWN NA

DBS for Treatment Resistant Depression

NCT01983904

Depressive Disorder, Treatment-Resistant

COMPLETED NA

Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)

NCT01898429

Treatment Resistant Depression Depressive Disorder, Treatment-Resistant Depression, Bipolar

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The first phase of the study will consist of implanting electrodes. Recruited patients will be random to 2 targets: (1) medial prefrontal cortex (mPFC); (2) nucleus accumbens (NAcc). Continuous stimulation will be applied until the patients stabilise clinically. This period is anticipated between 6 and 9 months.

After this stage, the next phase will consist of the crossover study. Those patients who respond to DBS will be randomly distributed in two groups, for a period of 3 months: on stimulation group and off stimulation group. Patients will then be crossed over to the other group for a further 3 months.

Weekly visits during first month after, and fortnightly visits will be made during the entire study to evaluate treatment efficacy and patient tolerance.

Patients who complete the study and respond to treatment with DBS will be provided continuing with treatment, and keeping control visits to assess the long-term effectiveness.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Refractory Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

On-Stimulation

Disease condition is assessed with stimulation turned "on"

Group Type ACTIVE_COMPARATOR

On-Stimulation

Intervention Type DEVICE

The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is "on"

Off-Stimulation

Disease condition is assessed with stimulation turned "off"

Group Type PLACEBO_COMPARATOR

Off-Stimulation

Intervention Type DEVICE

The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is "off"

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

On-Stimulation

The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is "on"

Intervention Type DEVICE

Off-Stimulation

The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is "off"

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female aged between 18 and 55 years.
2. DSM IV-TR diagnosis of schizophrenia for at least 3 years prior to the screening visit.
3. Determined to be treatment-resistant as demonstrated by:

1. Persistence of positive symptoms which have not responded to appropriate treatments for at least 2 years.
2. Inadequate response from adequate trials of two different classes of antipsychotic drugs (not including clozapine), at least 8 weeks.
3. Inadequate response from adequate trial of clozapine, at least 3 months, or unable to tolerate clozapine because of intolerable side effects.
4. ECT is contraindicated or have failed to produce a maintained response.
4. Persistence of positive symptoms defined as i) requiring a score of 4 (mild) or more on at least 2 of the next PANSS items: delusions, hallucinatory behavior, suspiciousness and unusual thought content; or as ii) requiring a score of 6 (severe) or more on at least 1 of the above PANSS items.
5. Current CGI score 6 or more
6. Stable antipsychotic treatment for last 2 months.
7. Women of childbearing age using medically approved contraceptive methods.
8. Adequate familiar or social support during all study procedures.

Exclusion Criteria

1. MRI (Magnetic Resonance Imaging) contraindication to stimulation or contraindications for MRI
2. History of epilepsy or clozapine-induced seizures, where use of anticonvulsants was needed
3. Current suicidal ideation, plan or intent for self-harm during last 2 months.
4. Evidence of global cognitive impairment.
5. Current acute, serious or unstable illnesses.
6. History of substance abuse (other than tobacco or caffeine).
7. Comorbid axis I or II DSM IV-TR disorders.
8. Female patients who are pregnant or breastfeeding.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No